Slide 0
Turning the tide on
cancer drug costs
A rising tide of new cancer
drugs helps patients.
>700%
117
Since 1990,
new cancer drugs have
been approved in the US.
2
50
Another
could reach the market by 2020.1
3
This wave of innovation
could drown payers.
To hold back the tide of oncology drug costs, payers …
... limit patient access
Since 2006, NICE has issued negative
recommendations for
of the cancer
drugs reviewed.3
41%
4
The increase in the median monthly cost
of cancer drugs in the US since 1990 2
... experiment with new models
$
US payers test indication-specific
pricing, taking advantage of
four new drug value tools.
Innovative risk-sharing agreements
are another way to turn the tide.
The number of
risk-sharing contracts
created in the
UK and Italy since 2006
90
65%
of the contracts
are for cancer
drugs.4
These contracts are complex to
build, but can provide a strong
foundation for patient access.
Sources: 1 U.S. Food & Drug Administration, Memorial Sloan Kettering Cancer Center, Decision Resources. 2 Peter Bach, Memorial Sloan Kettering Cancer Center,
Center for Health Policy and Outcomes, "Price and Value of Cancer Drug," 2015. 3 EY, National Institute for Health and Care Excellence (NICE).
4
Van de Vooren, et al., “Market-access agreements for anti-cancer drugs,” J R Soc Med (108): 166–170, 2015.
© 2015 EYGM Limited. All Rights Reserved. EYG no. FN0236. ED None
1
Slide 1
